Financial Performance Summary The company reports a substantial accumulated deficit of approximately \(400 Million. While overall net losses have narrowed significantly year-over-year (Diluted Net Loss YTD improved to \)30.10M from \(50.18M), total segment expenses increased year-over-year to \)30.75M (from \(19.44M). A major swing occurred in non-operating results, shifting from \)30.74M income in 2024 to a \(27.79M expense in 2025. Stock-Based Compensation expense increased substantially to \)3.756M. Operational costs surged, with Drug Manufacturing Costs reaching $5.96M and Clinical Trial Expen
...